Difference between revisions of "Team:Queens Canada/Circ AFP"
(3 intermediate revisions by the same user not shown) | |||
Line 47: | Line 47: | ||
</div> | </div> | ||
− | <div class="intro" style="padding: | + | <div class="intro" style="padding: 60px 200px 20px 200px;"> |
<h1>ICEFINITY: CIRCULARIZED AFP</h1> | <h1>ICEFINITY: CIRCULARIZED AFP</h1> | ||
Line 57: | Line 57: | ||
<h2>Design & Cloning</h2> | <h2>Design & Cloning</h2> | ||
− | <p>A thorough dry lab analysis was performed to determine the appropriate linker needed to circularize the AFP. Details about this crucial dry lab stage are described on our Modeling Page | + | <p>A thorough dry lab analysis was performed to determine the appropriate linker needed to circularize the AFP. Details about this crucial dry lab stage are described on our <a href="https://2015.igem.org/Team:Queens_Canada/Modeling">Modeling Page</a>. After selecting the optimal linker (GAA), The AFP-linker-extein insert sequence was then designed to be compatible with the Golden Gate Assembly technique necessary for BBa_K1362000; BsaI cut sites were placed on the ends of the insert sequence to allow for successful insertion into Heidelberg’s BioBrick. The final designed insert is illustrated below in Figure 1.</p> |
<figure style="width:400px; float: right;"> | <figure style="width:400px; float: right;"> | ||
Line 79: | Line 79: | ||
<figure style="width:600px; display: block; margin-left: auto; margin-right: auto;"> | <figure style="width:600px; display: block; margin-left: auto; margin-right: auto;"> | ||
− | <img src=" | + | <img src="https://static.igem.org/mediawiki/2015/8/80/Qqq_QGM_circAFPexpression.png" style="width:600px; display: block; margin-left: auto; margin-right: auto;"> |
<figcaption style="margin-left: 30px;">Figure 3. <strong>SDS-PAGE of unpurified cell lysate components for both wild-type (WT) and circular AFP: supernatant (sup), pellet, and total cell lysate (TCL). </strong>First three columns show the WT AFP, and last three columns show the circAFP. Although the circAFP contains several additional amino acids, it appears to have run further down the gel. Similar results were visualized by the Heidelberg iGEM team in 2014. Cyclized proteins run further than their linear counterparts because of their more compact shape; this allows for the protein to travel through the gel much faster. </figcaption> | <figcaption style="margin-left: 30px;">Figure 3. <strong>SDS-PAGE of unpurified cell lysate components for both wild-type (WT) and circular AFP: supernatant (sup), pellet, and total cell lysate (TCL). </strong>First three columns show the WT AFP, and last three columns show the circAFP. Although the circAFP contains several additional amino acids, it appears to have run further down the gel. Similar results were visualized by the Heidelberg iGEM team in 2014. Cyclized proteins run further than their linear counterparts because of their more compact shape; this allows for the protein to travel through the gel much faster. </figcaption> | ||
Line 87: | Line 87: | ||
<figure style="width: 400px; float: left; margin-top: 50px;"> | <figure style="width: 400px; float: left; margin-top: 50px;"> | ||
− | <img src=" | + | <img src="https://static.igem.org/mediawiki/2015/9/9d/Qqq_QGEM_rightcircAFPse.png" style="width: 400px;" /> |
<figcaption>Figure 4. <strong>SDS-PAGE of the size exclusion column fractions, depicting the purified circAFP (Fraction A9).</strong> </figcaption> | <figcaption>Figure 4. <strong>SDS-PAGE of the size exclusion column fractions, depicting the purified circAFP (Fraction A9).</strong> </figcaption> | ||
</figure> | </figure> | ||
<figure style="width: 350px; float: right; "> | <figure style="width: 350px; float: right; "> | ||
− | <img src=" | + | <img src="https://static.igem.org/mediawiki/2015/2/23/Qqq_QGEM_AFPIAP.png" style="width: 260px;"/> |
<figcaption>Figure 5. <strong>SDS-PAGE of ice-affinity purified circAFP</strong>. This gel illustrate the results of one round of IAP. The single band in the last lane indicates the purified circAFP, isolated in the ice fraction. The liquid fraction represents all compounds not incorporated into the ice. </figcaption> | <figcaption>Figure 5. <strong>SDS-PAGE of ice-affinity purified circAFP</strong>. This gel illustrate the results of one round of IAP. The single band in the last lane indicates the purified circAFP, isolated in the ice fraction. The liquid fraction represents all compounds not incorporated into the ice. </figcaption> | ||
</figure> | </figure> | ||
Line 101: | Line 101: | ||
<figure style="float: right; width: 500px;"> | <figure style="float: right; width: 500px;"> | ||
− | <img src=" | + | <img src="https://static.igem.org/mediawiki/2015/b/ba/Qqq_QGEM_thgraph.png" style="float: right; width: 500px;"/> |
<figcaption>Figure 6. <strong>Bar graph of TH assay results, comparing wtAFP with our circAFP at various activity test conditions. </strong>Data shows that circAFP retains almost 80% of its antifreeze activity after being subjected to 90 <sup>o</sup>C . The wild-type AFP quickly loses its activity after exposure to such high temperatures. </figcaption> | <figcaption>Figure 6. <strong>Bar graph of TH assay results, comparing wtAFP with our circAFP at various activity test conditions. </strong>Data shows that circAFP retains almost 80% of its antifreeze activity after being subjected to 90 <sup>o</sup>C . The wild-type AFP quickly loses its activity after exposure to such high temperatures. </figcaption> | ||
</figure> | </figure> |
Latest revision as of 00:10, 18 September 2015